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LETTER TO THE EDITOR
Malignant Pleural
and Peritoneal
Mesothelioma:
Incidental Diagnosis
and Excellent
Treatment Results
To the Editor:
Patients with malignant pleural and
peritoneal mesothelioma usually present
with advanced symptomatic disease.1
Prognosis is poor. During our practice
we had an exceptional mesothelioma case.
During cholecystectomy peritoneal biopsy
was done due to infiltration of omentum
for 56-year-old man. The biopsy analysis
showed that patient had peritoneal me-
sothelioma (Figure 1). The second me-
sothelioma marker WT-1 was positive
and other markers (CEA, CD-15, and
TTF-1) were negative. There were no
respiratory symptoms or history of as-
bestos exposure. The patient (former
smoker) was in good functional status.
Chest computed tomography (CT) scan
revealed multinodal lesions of left pleura
(Figure 2). Malignant pleural and perito-
neal mesothelioma was diagnosed and
treatment with permetrexed 500 mg/m2
day 1 and cisplatin 80 mg/m2 day 1 (for
1 cycle) every 21 day was prescribed.
The patient was assessed regularly with
chest and abdomen CT (according to the
modified RECIST criteria2). The pleural
signs of mesothelioma disappeared com-
pletely after six cycles. No pleural or peri-
toneal changes were seen on CT scan 6
months after completion of chemotherapy
(Figure 3). The patient is still alive with no
signs of disease progression 3 years later.
Early retrospective studies reported
5-year survival rates of 1% and overall
median survivals of 7.6 months for pa-
tients not receiving chemotherapy. Eight
randomized clinical trials concerning the
mesothelioma chemotherapy have been
published. Vogelzang et al.3 treated 448
eligible patients with either permetrexed
and cisplatin or cisplatin alone. Response
rates (41%versus 17%, p was 0.001),
time to progression (5.7 versus 3.9
months, p was 0.001), and survival (me-
dian, 12.1 versus 9.3 months; hazard
ratio 0.77, p was 0.020) all favored the
combination treatment. In another large
phase III trial,4 250 patients were ran-
domized to receive either raltitrexed and
cisplatin or cisplatin alone. Overall re-
sponse rates (24% versus 14%, p was
0.056) was greater in the combination
treatment arm. Now permetrexed com-
bined with platinum compound is the
only recommended treatment for ex-
tensive mesothelioma. According to the
data of clinical trials the complete re-
sponse during first line chemotherapy in
malignant pleural mesothelioma is ex-
tremely rare. Furthermore, we could not
find any reported data concerning the
complete response rate in randomized
clinical trials with permetrexed treat-
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FIGURE 1. A, Positive membrane reaction with antibodies to epithelial membrane
antigen (EMA) (40 times power field); B, Moderate size atypical cells in solid areas
form the tumor. The cells form rare primitive glandular-like structures. Hematoxy-
lin and eosin (HE) stain (40 times power field); C, Diffuse nucleocytoplasmic label-
ing for Calretitin (40 times power field).
FIGURE 2. Lung computed tomography (CT): lung (A) and mediastinal window
(B): multinodal and confluent tumor of the left chest is apparent.
FIGURE 3. Lung computed tomography (CT): lung (A) and mediastinal window
(B): tumor of the left chest completely disappeared.
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ment. In July 2008, the results of multi-
center nonrandomized open-label study
with the largest group of chemonaïve
patients were reported under the Inter-
national Expanded Access Program in
Europe.5 The patients treated with per-
metrexed plus cisplatin (n  843) or
permetrexed plus carboplatin experi-
enced overall response rates of 26.3 and
21.7% and complete response was seen
in only 15 cases (2.0%) and 7 (0.9%)
cases respectively.
We can conclude that the pre-
sented case could be more an exception
than a rule. Sometimes in malignant pleu-
ral mesothelioma dramatic improvement
and complete response can be observed
during treatment with permetrexed and
cisplatin.
Skaidrius Miliauskas, MD, PhD
Marius Zemaitis, MD, PhD
Darius Pranys, MD
Kaunas University of Medicine
Lithuania
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ERRATUM
In the article “Primary Tracheal Lymphoma Causing Respiratory Failure,” which appeared in volume 3 of the Journal of Thoracic Oncology on pages
929-930, an author’s name was incorrect. The author’s name should have appeared as Soon Thye Lim.
Tan DS, Eng PC, Thye LM, Tao M. Primary Tracheal Lymphoma Causing Respiratory Failure. J Thorac Oncol. 2008;3:929-930.
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